Eculizumab
- TRADE NAME: Soliris (Alexion)
- INDICATIONS: Paroxysmal nocturnal hemoglobinuria; atypical hemolytic uremic syndrome
- CLASS: Complement inhibitor, Covid-19 putative drug, Monoclonal antibody
- HALF-LIFE: ~12 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
PREGNANCY CATEGORY: C
Investigated for treating COVID-19.
SERIOUS MENINGOCOCCAL INFECTIONS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTIC.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric